Event Details
January 01, 2007
Description
Celgene reported that only 100 prescriptions a year were being written for Thalomid to treat the approved skin condition.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| Celgene | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_028417.jpg
This document is a data extract, likely from a news article, which has been marked as an exhibit for a House Oversight investigation. The text details the history of the pharmaceutical company Celgene and its drug Thalomid (thalidomide), including its approval by the F.D.A. in 1998 and the context of executive Bob Hugin's subsequent political career. The document contains no information related to Jeffrey Epstein or his associates.
Related Events
Events with shared participants
The F.D.A. approved Celgene's application to treat erythema nodosum leprosum, a complication of leprosy, with its drug Thalomid (thalidomide).
1998-01-01 • United States
Mr. Hugin arrived at Celgene, which was struggling to profit from its only marketed drug, Thalomid.
1999-01-01 • New Jersey
Celgene's application was approved by the F.D.A. to treat erythema nodosum leprosum, a complication of leprosy.
1998-01-01 • United States
Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalomid.
1999-06-01 • New Jersey
Celgene reported that only about 100 prescriptions per year were written for the approved skin condition (leprosy complication).
2007-01-01 • United States
Celgene reported that 92 percent of Thalomid's prescriptions were being written to treat cancer, despite lack of formal approval for those uses.
2001-01-01
Celgene received formal approval to market Thalomid and Revlimid for certain cancers.
2005-01-01
Revlimid was introduced to the market at an initial cost of about $6,000 per month.
2006-01-01
Celgene settled a lawsuit regarding illegal marketing to avoid protracted litigation.
2017-01-01
Celgene raised the price of a month's supply of Revlimid to more than $16,000.
Date unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event